http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2012225232-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bf14b1a1c7c3ae2b6ed5700a3055d2d |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/F16M11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/F16M11-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B66C1-42 |
filingDate | 2012-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2780462a6ac1df0cc9c568700d68ecb |
publicationDate | 2013-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2012225232-A1 |
titleOfInvention | Prostate cancer cell lines, gene signatures and uses thereof |
abstract | The present disclosure, in part, is directed to a mammalian prostate cancer cell line comprising at least one or a set of primary mammalian epithelial cells which have been infected with a retroviral vector carrying an oncogene selected from the group consisting of c-Myc, Ha-Ras, NeuT, c-Src and combinations thereof and in which said gene is expressed. Applications of the prostate cell lines, including immune competent animal models of prostate cancer, a method for the in vitro production of immortalized primary mammalian epithelial cells, a method of determining whether a human subject having prostate cancer is suffering from or at risk for developing metastasis, a method of preventing cancer or inhibiting metastasis of cancer susceptible to treatment in a subject at risk for developing cancer or metastasis of cancer, and method of identifying a candidate compound that selectively interferes with proliferation or viability of a cancer cell that has elevated levels of CCR5 and/or of at least one of its ligands. |
priorityDate | 2011-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 283.